MX2023001415A - Composiciones y métodos relacionados con la unión al receptor de il27. - Google Patents

Composiciones y métodos relacionados con la unión al receptor de il27.

Info

Publication number
MX2023001415A
MX2023001415A MX2023001415A MX2023001415A MX2023001415A MX 2023001415 A MX2023001415 A MX 2023001415A MX 2023001415 A MX2023001415 A MX 2023001415A MX 2023001415 A MX2023001415 A MX 2023001415A MX 2023001415 A MX2023001415 A MX 2023001415A
Authority
MX
Mexico
Prior art keywords
compositions
receptor binding
methods related
sub
il27rî
Prior art date
Application number
MX2023001415A
Other languages
English (en)
Spanish (es)
Inventor
Deepti Rokkam
Patrick J Lupardus
Robert Kastelein
Original Assignee
Synthekine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc filed Critical Synthekine Inc
Publication of MX2023001415A publication Critical patent/MX2023001415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023001415A 2020-08-05 2021-08-04 Composiciones y métodos relacionados con la unión al receptor de il27. MX2023001415A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063061562P 2020-08-05 2020-08-05
US202063078745P 2020-09-15 2020-09-15
US202163135884P 2021-01-11 2021-01-11
PCT/US2021/044577 WO2022031871A1 (en) 2020-08-05 2021-08-04 Compositions and methods related to il27 receptor binding

Publications (1)

Publication Number Publication Date
MX2023001415A true MX2023001415A (es) 2023-04-24

Family

ID=92301997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001415A MX2023001415A (es) 2020-08-05 2021-08-04 Composiciones y métodos relacionados con la unión al receptor de il27.

Country Status (9)

Country Link
US (2) US11873349B1 (https=)
EP (1) EP4192502A4 (https=)
JP (2) JP7665730B2 (https=)
KR (2) KR102875986B1 (https=)
CN (2) CN116829585A (https=)
AU (1) AU2021322238A1 (https=)
CA (1) CA3190420A1 (https=)
MX (1) MX2023001415A (https=)
WO (1) WO2022031871A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
MX2023001415A (es) * 2020-08-05 2023-04-24 Synthekine Inc Composiciones y métodos relacionados con la unión al receptor de il27.
EP4192490A4 (en) 2020-08-05 2025-01-01 Synthekine, Inc. IL27RA-BINDING MOLECULES AND METHODS OF USE
KR102773428B1 (ko) 2020-08-05 2025-02-28 신테카인, 인크. Il10 수용체 결합 분자 및 사용 방법
KR20250034106A (ko) * 2022-08-03 2025-03-10 화이자 인코포레이티드 항-il27r 항체 및 그의 사용 방법
WO2024232655A1 (ko) 2023-05-11 2024-11-14 주식회사 엘지에너지솔루션 배터리셀의 포메이션 장치
WO2025030130A1 (en) * 2023-08-03 2025-02-06 Chroma Medicine, Inc. Methods and compositions comprising dnmt3a-binding antibodies
KR20260011639A (ko) * 2024-07-16 2026-01-23 서울대학교산학협력단 Il27 저해제를 이용한 sfts 바이러스 감염증 개선용 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
US20060177436A1 (en) * 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
EP2650311A3 (en) * 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2010118243A2 (en) * 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140155581A1 (en) 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013059299A1 (en) 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN115160441A (zh) * 2013-09-26 2022-10-11 埃博灵克斯股份有限公司 双特异性纳米抗体
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN107400166A (zh) 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US11377497B2 (en) 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
EP3634465A4 (en) 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
SG11202005146VA (en) * 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
SG11202008731XA (en) * 2018-06-19 2020-10-29 Nanjing Legend Biotech Co Ltd Engineered cells and uses thereof
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN111018985B (zh) 2019-12-06 2021-06-18 南京融捷康生物科技有限公司 针对牛血清白蛋白bsa的单域抗体的应用
MX2023001415A (es) * 2020-08-05 2023-04-24 Synthekine Inc Composiciones y métodos relacionados con la unión al receptor de il27.
EP4200339A4 (en) * 2020-08-05 2025-04-30 Synthekine, Inc. Compositions and methods related to receptor pairings

Also Published As

Publication number Publication date
KR20230061390A (ko) 2023-05-08
JP7829773B2 (ja) 2026-03-13
KR20250159059A (ko) 2025-11-07
CN116829585A (zh) 2023-09-29
JP2023536651A (ja) 2023-08-28
KR102875986B1 (ko) 2025-10-24
EP4192502A4 (en) 2024-10-09
WO2022031871A4 (en) 2022-03-10
EP4192502A1 (en) 2023-06-14
JP7665730B2 (ja) 2025-04-21
BR112023001737A2 (pt) 2023-02-28
WO2022031871A1 (en) 2022-02-10
CN116723859A (zh) 2023-09-08
US11873349B1 (en) 2024-01-16
US20240209101A1 (en) 2024-06-27
CA3190420A1 (en) 2022-02-10
US20240002542A1 (en) 2024-01-04
JP2025108521A (ja) 2025-07-23
AU2021322238A1 (en) 2023-03-23
US12209132B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
MX2023001415A (es) Composiciones y métodos relacionados con la unión al receptor de il27.
WO2022150791A3 (en) Compositions and methods related to il2 receptor binding
WO2022055641A3 (en) Compositions and methods related to receptor pairings
ZA200806610B (en) Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6ralpha to GP130
WO2024081544A3 (en) Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2
PH12021552538A1 (en) Heavy chain antibodies binding to psma
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
PE20240638A1 (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
WO2022150788A3 (en) Compositions and methods related to receptor pairing
CR20220598A (es) Anticuerpos específicos para kras y sus usos
WO2022162518A3 (en) Psma binding proteins and uses thereof
ZA202408121B (en) Anti-human il-4ra antibody and application thereof
PH12022553387A1 (en) Bispecific immune cell engagers with binding specificity for hla-g and another antigen
AU2024221322A1 (en) Antibodies that bind interleukin 4 receptor alpha and methods of use
ZA202401100B (en) Human interleukin-4 receptor alpha antibodies
MX2023006650A (es) Anticuerpos multiespecificos y combinaciones de anticuerpos.
MX2026002880A (es) Composicion farmaceutica que comprende un anticuerpo biespecifico que se une especificamente a gprc5d y cd3
MX2025009399A (es) Anticuerpos caninos para il-13 canino
JOP20240153A1 (ar) المواد والطرق المتعلقة بالبروتينات الرابطة لإنترلوكين 1 بيتا (il-1 beta)
MX2023007629A (es) Muteinas de il-2 para el tratamiento contra enfermedades autoinmunitarias e inflamatorias.
MX2025014531A (es) Moléculas humanizadas de unión a receptor de il-10 y métodos de uso
WO2023028612A3 (en) Anti-tslpr (crlf2) antibodies